Tech Transfer Deals, September 2015
This article was originally published in Start Up
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Tech Transfer Deals column provides a monthly review of licensing agreements between companies and universities or other research institutions in the In Vitro Diagnostics, Medical Device, and Pharmaceutical sectors. This month’s column covers deals announced July through August 2015.
You may also be interested in...
Six $1bn+ alliances were penned in June. Topping the list was Eisai’s potential $3.1bn collaboration Bristol-Myers Squibb for the co-development and co-commercialization of Eisai’s antibody drug conjugate MORAb-202 in Japan, China, select countries in the Asia-Pacific region, the US, Canada, Europe (including the EU and UK), and Russia. The candidate is in Phase I in Japan and Phase I/II in the US for anti-folate receptor alpha-positive solid tumors.
In conducting pharma market opportunity assessments, there are several best practices that exist and common mistakes to avoid. In Vivo shares expert learnings from Pharma Intelligence’s Custom Intelligence leaders.
Four $1b+ alliances were penned in May. Topping the list was Bristol-Myers Squibb’s deal with Agenus under which BMS will be granted a global exclusive license to the late-preclinical antibody program AGEN1777 along with a second undisclosed target. Agenus received a $200m up-front payment and could get up to $1.36bn in development, regulatory, and commercialization milestones, plus tiered royalties in the low double-digit to mid-teen range.